发明名称 Pharmaceutical composition for treating autosomal dominant polycystic kidney disease
摘要 Background: Autosomal dominant polycystic kidney disease (ADPKD) shows a characteristic that kidney function is lost by abnormal proliferation of kidney epithelial cells. Even with the confirmation of gene which causes the ADPKD, effective medicine for the disease has not found so far. The functions of multidrug-resistance associated protein 3 (MRP3) in kidney are merely known. Method: RNAi system and Abcc3 clone for restoration are used to check the functions of the MRP3 in kidney. Fluorescent immunohistochemistry is performed to estimate expression of MRP3 in vivo. Result: MRP3 inhibition by MK571 or siRNA stimulates cell proliferation through ERK/B-Raf signaling pathway. In addition, expression of MRP3 in vivo is confirmed. MRP3 in kidneys of ADPKD patients is down regulated. However, restoration of the MRP3 reduces proliferation and cystogenesis in vitro. Conclusion: Such result tells that the functions of the MRP3 in kidney are related to cell proliferation, and restoration of the MRP3 is effective in polycystic kidney disease treatment.
申请公布号 KR101395148(B1) 申请公布日期 2014.05.15
申请号 KR20120105911 申请日期 2012.09.24
申请人 发明人
分类号 A61K31/7105;A61K38/16;A61K38/17;A61K48/00 主分类号 A61K31/7105
代理机构 代理人
主权项
地址
您可能感兴趣的专利